New Treatments for Metastatic Prostate Cancer
The FDA has approved 2 new treatments for castration-resistant (formerly called hormone-refractory)
prostate cancer. Sipuleucel-T (Provenge – Dendreon) is the first immunotherapy approved for treatment of prostate cancer. Cabazitaxel (Jevtana – Sanofi-Aventis) is approved for second-line treatment of
metastatic castration-resistant prostate cancer previously treated with docetaxel (Taxotere)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: New Treatments for Metastatic Prostate Cancer
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1346
Article Code: 1346b
Date: September 6, 2010
Volume: 52
Pages: 69-70
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1346
Article Code: 1346b
Date: September 6, 2010
Volume: 52
Pages: 69-70
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)